BioCentury
ARTICLE | Company News

Aestus Therapeutics, Astellas deal

September 26, 2011 7:00 AM UTC

Astellas' Prosidion Ltd. subsidiary granted Aestus exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of the glycogen phosphorylase inhibitor in post-herpetic neuralgia (PHN) by the end of 2012. Terms were not disclosed. Astellas acquired PSN357 through its acquisition of OSI Pharmaceuticals Inc. last year (see BioCentury, June 14, 2010). ...